Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis

Sahmin Lee,1 Seung-Ah Lee,1 Bongkun Choi,2 Ye-Jee Kim,3 Soo Jin Oh,4 Hong-Mi Choi,5 Eun Kyoung Kim,6 Dae-Hee Kim,1 Goo-Yeong Cho,5 Jong-Min Song,1 Seung Woo Park,6 Duk-Hyun Kang,1 Jae-Kwan Song,1

ABSTRACT

Objective To evaluate whether the use of dipeptidyl peptidase-4 (DPP-4) inhibitors and their cardiac tissue distribution profile and anticalcification abilities are associated with risk of aortic stenosis (AS) progression.

Methods Out of the five different classes of DPP-4 inhibitors, two had relatively favourable heart to plasma concentration ratios and anticalcification ability in murine and in vitro experiments and were thus categorised as ‘favourable’. We reviewed the medical records of 212 patients (72±8 years, 111 men) with diabetes and mild-to-moderate AS who underwent echocardiographic follow-up and classified them into those who received favourable DPP-4 inhibitors (n=28, 13%), unfavourable DPP-4 inhibitors (n=69, 33%) and those who did not receive DPP-4 inhibitors (n=115, 54%).

Results Maximal transaortic velocity (Vmax) increased from 2.9±0.3 to 3.5±0.7 m/s during follow-up (median, 3.7 years), and the changes were not different between DPP-4 users as a whole and non-users (p=0.143). However, the favourable group showed significantly lower Vmax increase than the unfavourable or non-user group (p=0.018). Severe AS progression was less frequent in the favourable group (7.1%) than in the unfavourable (29.0%; p=0.03) or the non-user (29.6%; p=0.01) group. In Cox regression analysis after adjusting for age, baseline renal function and AS severity, the favourable group showed a significantly lower risk of severe AS progression (HR 0.116, 95% CI 0.024 to 0.551, p=0.007).

Conclusions DPP-4 inhibitors with favourable pharmacokinetic and pharmacodynamic properties were associated with lower risk of AS progression. These results should be considered in the preparation of randomised clinical trials on the repositioning of DPP-4 inhibitors.

INTRODUCTION

Calcific aortic stenosis (AS) is the most common valvular heart disease in developed countries, but there are currently no effective medical treatments that can stop or delay AS progression.1 The only available treatment option is replacing the aortic valve by open heart surgery or transcatheter valve implantation in patients with severe AS, which routinely allows the development of an end-stage, irreversible disease. The aortic valve had been traditionally regarded as a metabolically inactive tissue, and clinicians thus believed that AS is a typical example of a degenerative disease associated with ageing. However, the identification of valvular interstitial cells (VICs) with potential to differentiate into osteoblast-like cells in human aortic valves resulted in a major paradigm shift, and AS is now regarded as a metabolically active disease.2,3

Our group recently reported that endothelial dysfunction in aortic valve leads to increased expression of dipeptidyl peptidase-4 (DPP-4), which induces the degradation of insulin-like growth factor-1 (IGF-1) and subsequent osteogenic differentiation of VICs.4 As DPP-4 inhibitors are currently used for management of type 2 diabetes, researchers have suggested that DPP-4 inhibitors may be repositioned to manage other diseases including AS.1,4 Analytical clinical data from patients with diabetes who received DPP-4 inhibitors may provide valuable information on whether DPP-4 inhibitors may be useful for preventing AS progression. We thus evaluated the factors that are potentially associated with the therapeutic efficacy of DPP-4 inhibitors for AS. Specifically, we tested whether the cardiac tissue distribution profile of DPP-4 inhibitors and their direct anticalcification effect on VICs are associated with efficacy.

METHODS

Experimental animals

The animal (Sprague-Dawley rat) was a standard species routinely used in pharmacokinetic evaluations, and the number of animals used in the study was the minimum necessary to properly perform plasma pharmacokinetic evaluation.

We tested the cardiac tissue distribution of eight different DPP-4 inhibitors using male Sprague-Dawley rats (7–9 weeks old), which were equally divided according to each inhibitor (online supplementary table 1). The DPP-4 inhibitors were weighed and mixed with appropriate volume (1 mL/kg) of vehicle to obtain uniform clear solutions. Two 20 µL aliquots of each formulation were used for dose validation by either liquid chromatography with ultraviolet detection (LC/UV) or liquid chromatography with tandem mass spectrometry (LC-MS/MS). The solutions were prepared on the day of dosing and were administered via the tail vein within 4 hours after preparation (online supplementary data). We also tested in vitro the anticalcifying efficacy of eight DPP-4 inhibitors (five of which were used in the retrospective patient study) using human aortic VICs (online supplementary table 1).
We assumed that the concentration of DPP-4 inhibitors within the heart would have to be higher than the half-maximal anti-calciﬁng effective concentration (EC50) in order to exert a signiﬁcant effect on aortic VICs. Thus, using both pharmacokinetic and pharmacodynamic data, we calculated the adjusted H:P ratio (heart to plasma concentration ratio at 4 hours × [heart concentration at 4 hours/EC50]) for each DPP-4 inhibitor to compare their theoretical efficacy on VICs to prevent AS progression.

Patient data
Electronic medical records and echocardiographic database of three tertiary referral hospitals in South Korea (Asan Medical Center, Seoul; Samsung Medical Center, Seoul; Seoul National University Bundang Hospital, Gyeonggi-do) from 2009 and 2016 were retrospectively screened to identify patients with type 2 diabetes with mild- to- moderate AS. Mild- to- moderate AS was deﬁned as initial maximal transaortic velocity (Vmax) between 2.5 and 3.5 m/s and normal left ventricular systolic function (left ventricular ejection fraction >50%). We further screened for patients who underwent follow-up echocardiographic examination at intervals of more than 2 years. Exclusion criteria included the presence of other haemodynamically signiﬁcant valvular lesions that may affect the Vmax, decreased left ventricular systolic function by more than 10% during the follow-up and end-stage renal disease. Patients who did not receive speciﬁc diabetes medication during echocardiographic follow-up duration were also excluded. The ﬂow diagram for patient selection is shown in ﬁgure 1. The need for informed consent was waived due to the retrospective nature of the study.

From the electronic medical records, we extracted the demographic information, blood test results and diabetes medications of the patients. We also extracted echocardiographic data regarding AS severity; Vmax and peak transaortic pressure gradient were, respectively, deﬁned as the highest velocity and pressure gradient obtained from multiple windows. The mean pressure gradient was determined by tracing the contour of the aortic jet obtained by continuous-wave Doppler imaging. Progressions of AS severity—annual changes in Vmax as well as peak and mean pressure gradients—were calculated using the ﬁnal echocardiographic data from baseline assessments. Systematic case report forms were ﬁlled by dedicated research nurses and physicians. Clinical follow-up data were included in the case report forms. Development of clinical events included progression to severe AS (deﬁned as follow-up Vmax ≥4 m/s) and aortic valve intervention by either surgical or transcatheter replacement.

Patient and public involvement
Patients were not involved in the study design.

Statistical analysis
Patient characteristics were compared using the χ2 test or the Student’s t-test between the non-user and user of DPP-4.
Valvular heart disease

inhibitors. Discrete variables were reported as numbers with percentages and continuous variables were expressed as mean and SD. For comparison of annual progression of AS severity, analysis of variance test was performed among the three groups of study population (non-user group, favourable DPP-4 inhibitor group and unfavourable DPP-4 inhibitor group). To minimise the baseline differences between patients who received favourable DPP-4 inhibitors and those without, a propensity score matching was used using a logistic model including age, sex, dyslipidaemia, coronary artery disease, baseline glomerular filtration rate, baseline aortic valve mean pressure gradient, follow-up duration, and use of statin and antidiabetic drugs (sulfonylurea, metformin or insulin) as covariates. After calculating the predicted probabilities, we matched each favourable DPP-4 inhibitor user (n=25) to two non-user groups (n=50) using the Greedy algorithm (online supplementary table 2). Model discrimination was assessed with C statistics (0.776), and model calibration was assessed with Hosmer-Lemeshow statistics ($\chi^2=7.2941$, df=8, $p=0.5053$). Multivariate analysis was performed with adjustment of covariance; covariates of $p<0.1$ and considered to be clinically significant were included in the model. The Tukey-Kramer method was applied to the post-hoc analysis for pairwise comparisons between the groups. Cox regression models were constructed to determine the factors associated with progression to severe AS. In the multivariate model, the covariates considered to be clinically significant were added. The final model included age, use of favourable or non-favourable DPP-4 inhibitors, baseline AS severity, and renal function. The probability of significance was judged based on $p<0.05$. All statistical analyses were performed using the SAS V9.4 software.

RESULTS

Anticalcification effect and cardiac tissue distribution profiles of DPP-4 inhibitors

Online supplementary table 1 shows the pharmacokinetic and pharmacodynamic profiles of each DPP-4 inhibitor, including the EC50 of anticalcification and the absolute heart and plasma concentrations at 1 and 4 hours after intravenous injection in rats. We selected five DPP-4 inhibitors used in our patient cohort, and their pharmacokinetic and pharmacodynamic properties are illustrated in figure 2. Most of the DPP-4 inhibitors significantly attenuated the osteogenic changes in human VICS from patients with AS (figure 2A). The H:P ratios of linagliptin and gemigliptin were significantly higher than those of alogliptin, sitagliptin and vildagliptin (figure 2B). When the ratio was adjusted by weighing on the absolute tissue concentration relative to the EC50 for anticalcification, the difference became greater (figure 2C,D). We thus classified the DPP-4 inhibitors as favourable (linagliptin and gemigliptin) and unfavourable (alogliptin, sitagliptin and vildagliptin) in the subsequent analysis. Of the eight DPP-4 inhibitors, evogliptin had the highest adjusted H:P ratio (online supplementary table 1), although this was not used in any of the patients in the clinical study.

Patients with diabetes and mild-to-moderate AS

A total of 1081 patients with mild-to-moderate AS and normal left ventricular systolic function were initially screened, and after applying the exclusion criteria 212 patients (mean age, 72±8 years; 111 men) were included in the analysis. One hundred and fifteen patients (54%) did not receive DPP-4 inhibitors (non-user group); 28 (13%) and 69 (33%) patients

![Figure 2](https://example.com/fig2.png)

Figure 2 Results of the pharmacokinetic and pharmacodynamic tests. (A) The dose–response curves for alkaline phosphatase (ALP) activity of human valvular interstitial cells (hVICs) after treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors after 1 week of osteogenic stimulation. (B) Heart to plasma concentration (H:P) ratio of the DPP-4 inhibitors at 4 hours after intravenous injection in rats (n=3 for each drug). (C,D) Adjusted H:P ratio of favourable (linagliptin and gemigliptin) and unfavourable (alogliptin, sitagliptin and vildagliptin) DPP-4 inhibitors.
Valvular heart disease

had received favourable and unfavourable DPP-4 inhibitors, respectively (figure 1).

Baseline clinical and echocardiographic characteristics are summarised in table 1. There were no significant differences in clinical risk factors among the three groups, except antidiabetic drugs including insulin. Nonetheless, the baseline and follow-up haemoglobin A1c were not significantly different among the groups. Age, sex, presence of coronary artery disease, use of statin and baseline estimated glomerular filtration rates, as well as use of metformin, sulfonylurea and insulin, were considered potential confounding variables and their effects were adjusted in the following analyses.

### Table 1  Comparison of patient baseline characteristics

|                     | Non-user (n=115) | DPP-4 inhibitor user (n=97) | Overall p value |
|---------------------|------------------|----------------------------|-----------------|
|                     | Unfavourable (n=69) | Favourable (n=28)       |                 |
| Age, years          | 72.8±8.1         | 70.3±8.5                   | 0.094           |
| Male, n (%)         | 61 (53.0)        | 36 (52.2)                  | 0.958           |
| Hypertension, n (%) | 97 (84.3)        | 65 (94.2)                  | 0.104           |
| Stage III or IV chronic kidney disease, n (%) | 16 (13.9) | 7 (10.1) | 0.363 |
| Coronary artery disease, n (%) | 45 (39.1) | 22 (31.9) | 16 (57.1) | 0.069 |
| Ischaemic stroke, n (%) | 16 (14.0) | 11 (15.9) | 2 (7.1) | 0.517 |
| Statin, n (%)       | 76 (66.1)        | 54 (78.3)                  | 0.092           |
| ACE inhibitor or ARB, n (%) | 75 (65.2) | 47 (68.1) | 23 (82.1) | 0.224 |
| Beta-receptor blocker, n (%) | 55 (47.8) | 34 (49.3) | 11 (39.3) | 0.657 |

**Exposure to antidiabetic drugs, n (%)**

|                     | Non-user (n=115) | DPP-4 inhibitor user (n=97) | Overall p value |
|---------------------|------------------|----------------------------|-----------------|
|                     | Unfavourable (n=69) | Favourable (n=28)       |                 |
| Metformin           | 80 (69.6)        | 63 (91.3)                  | 0.002*          |
| Thiazolidinediones  | 15 (13.0)        | 8 (11.6)                   | 0.925           |
| Sulfonylurea        | 67 (58.3)        | 36 (52.2)                  | 0.023†          |
| Meglitinides        | 8 (7.0)          | 4 (5.8)                    | 0.947           |
| Alpha-glucosidase inhibitors | 18 (15.7) | 7 (10.1) | 1 (3.6) | 0.175 |
| Insulin             | 47 (40.9)        | 8 (11.6)                   | <0.001*         |
| Baseline total cholesterol, mg/dL | 159.3±35.5 | 161.5±39.1 | 146.6±26.1 | 0.164 |
| Baseline LDL cholesterol, mg/dL | 96.3±30.0 | 96.3±30.0 | 93.4±22.3 | 0.769 |
| Baseline creatinine, mg/dL | 1.0±0.44 | 0.99±0.77 | 1.1±0.36 | 0.679 |
| Baseline eGFR       | 66.5±19.9        | 66.5±19.9                  | 0.063           |
| Baseline HbA1c, %   | 7.2±1.2          | 7.0±1.1                    | 0.536           |
| AV maximal velocity, m/s | 2.9±0.3 | 2.9±0.3 | 2.9±0.3 | 0.735 |
| AV mean pressure gradient, mm Hg | 18.2±4.5 | 18.9±5.1 | 18.8±5.5 | 0.755 |
| AV peak pressure gradient, mm Hg | 33.5±7.2 | 34.3±8.1 | 34.3±7.9 | 0.593 |

*P<0.017 for the pairwise comparison of non-user versus unfavourable DPP-4 inhibitor.
†P<0.017 for the pairwise comparison of non-user versus favourable DPP-4 inhibitor.

**AS progression**

Baseline Vmax and AS severity were not significantly different among the three groups and the mean baseline Vmax was 2.9±0.3 m/s (table 1). During a median echocardiographic follow-up of 3.7 years (IQR 2.8–5.1 years), Vmax increased to 3.5±0.7 m/s. The annual change in Vmax was not significantly different between the DPP-4 inhibitor user group and the non-user group (14.3±16.0 vs 17.8±17.1 cm/s/year, p=0.143) (online supplementary table 3). However, the favourable group showed significantly lower Vmax increase compared with the unfavourable group or non-user group (overall p=0.018). The annual change of mean (p=0.015) and peak

### Table 2  Haemodynamic progression of aortic stenosis according to use of antidiabetic drugs

|                     | Non-user (n=115) | DPP-4 inhibitor user (n=97) | Overall p value | Adjusted p value* |
|---------------------|------------------|----------------------------|-----------------|-------------------|
|                     | Unfavourable (n=69) | Favourable (n=28)       |                 |                   |
| Annual change of AV maximal velocity, cm/s/year | 17.7±17.1 | 16.9±15.9 | 8.0±13.0 | 0.018 | 0.015 |
| Annual change of mean pressure gradient, mm Hg/year | 3.2±3.2 | 2.7±2.7 | 1.3±3.0 | 0.015 | 0.022 |
| Annual change of peak pressure gradient, mm Hg/year | 5.2±5.3 | 4.8±5.0 | 2.3±4.0 | 0.027 | 0.025 |

*Adjusted for age, sex, coronary artery disease, use of statin, baseline estimated glomerular filtration rate, and use of metformin, sulfonylurea and insulin.

AV, aortic valve; DPP-4, dipeptidyl peptidase-4.
Valvular heart disease

(p=0.027) pressure gradient showed similar trends (table 2 and figure 3). In the post-hoc analysis, the favourable DPP-4 inhibitor group showed significantly lower Vmax change (8.0±13.0 cm/s/year) compared with the non-user group (17.8±17.1 cm/s/year, p=0.014) or the unfavourable group (16.9±15.9 cm/s/year, p=0.039) (online supplementary table 4). The differences were significant after adjustment for age, sex, coronary artery disease, use of statin, baseline estimated glomerular filtration rate level, and use of metformin, sulfonylurea and insulin (table 2 and online supplementary table 4). After propensity matching, use of favourable DPP-4 inhibitor was associated with significantly lower annual change of Vmax and mean and peak pressure gradient (online supplementary table 5).

During a median follow-up of 5.0 years (IQR 3.6–6.7 years), progression to severe AS was confirmed in 56 (26.4%) patients, of whom 27 underwent aortic valve intervention. In the non-user group, 34 (29.6%) had AS progression and 14 (12.2%) underwent aortic valve intervention; in the unfavourable group, 20 (29.0%) had severe AS progression and 11 (15.9%) underwent aortic valve intervention. In contrast, two (7.1%) patients had severe AS progression and underwent intervention in the

Figure 3  Changes of maximal transaortic valve velocity (A), mean (B) and peak (C) pressure gradient according to medications. Turkey’s method was used to make box plots. DPP-4, dipeptidyl peptidase-4.
favourable group. Thus, the favourable group had a significantly lower proportion of patients with severe AS progression than the non-user group (p=0.01) or the unfavourable group (p=0.03). In Cox regression analysis after adjusting for age, baseline renal function and baseline AS severity, use of favourable DPP-4 inhibitor had a significantly lower risk of progression to severe AS (adjusted HR 0.116, 95% CI 0.024 to 0.551, p=0.007) (table 3 and figure 4).

**DISCUSSION**

In our study, we categorised five DPP-4 inhibitors into favourable and unfavourable according to anticalcification abilities and cardiac tissue distribution profiles. Importantly, we found that among patients with diabetes and mild-to-moderate AS, those who received favourable DPP-4 inhibitors (ie, inhibitors with high anticalcification ability and high H:P ratios) had significantly lower degree of increase in Vmax as well as lower frequency of AS progression and aortic valve intervention than those who received unfavourable DPP-4 inhibitors or did not receive DPP-4 inhibitors. These results warrant the need for clinical trials on the repositioning of DPP-4 inhibitors for the management of AS.

AS is a progressive condition characterised by long asymptomatic phase; accordingly, AS has been traditionally regarded as a typical disease entity of prolonged ‘wear and tear’. Nevertheless, recent molecular studies showed that aortic valve has VICs with unique homeostatic mechanisms, and that valvular degeneration starts with active inflammation involving biochemical, humoral and genetic factors. As lipid-lowering agents failed to show efficacy in preventing AS progression, researchers have investigated potential therapeutic molecular targets including lipoprotein (a), apolipoprotein B oxidised phospholipid and interleukin 11. Similarly, the target of medical interventions has greatly expanded and ranges from the classic calcification (SALTIRE 2 trial using denosumab or bisphosphonate; NCT02132026) to the matrix before calcification (BASIK 2 trial targeting matrix γ-carboxyglutamyl acid protein; NCT02917525).

Our group previously reported that degradation of IGF-1 by DPP-4 is linked to progressive aortic valve calcification, and that reciprocal interactions between valvular endothelial cells and VICs are critical for the development of AS. In physiological condition, IGF-1 suppresses osteogenic transformation of aortic VICs. Importantly, endothelial dysfunction increased DPP-4 expression and promoter binding in aortic VICs, thereby leading to increased degradation of IGF-1 and subsequent osteogenic differentiation of VICs. Accordingly, treatment with DPP-4 inhibitor hindered the progression of aortic valve calcification in animal models of AS.

Among various molecular targets potentially associated with AS development and progression, the DPP-4–IGF-1 axis is particularly useful for drug repositioning as DPP-4 inhibitors are widely used in patients with diabetes. For successful drug repositioning of DPP-4 inhibitors as disease-modifying agents for AS, the anticalcification effect and the cardiac tissue distribution profile of different DPP-4 inhibitors need to be analysed and compared. The currently available DPP-4 inhibitors have been reported to have a similar degree of inhibition of DPP-4 activity and thus show comparable efficacy for diabetes control; however, we observed that antidiabetes efficacy and anticalcification efficacy were quite different even in the same drug. For example, the anticalcifying EC50 value of sitagliptin acquired from our in vitro study was 699 nM, whereas the half-maximal inhibitory concentration values for diabetes were reported to be in the range of 10–20 nM. This implies that higher plasma or tissue concentrations may be needed to have a sufficient therapeutic effect in AS than those for diabetes. Moreover, five DPP-4 inhibitors had marked heterogeneity in their in vivo H:P concentration ratios, although most of them were able to attenuate in vitro osteogenic changes significantly. These results suggest that the in vivo anticalcifying efficacy of different DPP-4 inhibitors may also be different, and for this reason pharmacokinetic and pharmacodynamic modelling will be a useful approach to estimate the proper effect of each DPP-4 inhibitor to prevent calcific

| Table 3 | Cox proportional regression models for aortic stenosis progression |
|---------|---------------------------------------------------------------|
|         | HR (95% CI) | P value |
| **Crude model** | | | 0.268 |
| Non-user (reference) | 1 | 0.268 |
| Unfavourable DPP-4 inhibitor | 1.054 (0.61 to 1.83) | 0.853 |
| Favourable DPP-4 inhibitor | 0.318 (0.08 to 1.33) | 0.117 |
| **Model 1 (adjusted for baseline AS severity)** | | | 0.041 |
| Non-user (reference) | 1 | 0.041 |
| Unfavourable DPP-4 inhibitor | 0.837 (0.61 to 1.83) | 0.536 |
| Favourable DPP-4 inhibitor | 0.148 (0.03 to 0.66) | 0.012 |
| **Model 2 (adjusted for baseline AS severity and age)** | | | 0.038 |
| Non-user (reference) | 1 | 0.038 |
| Unfavourable DPP-4 inhibitor | 0.870 (0.49 to 1.54) | 0.631 |
| Favourable DPP-4 inhibitor | 0.141 (0.03 to 0.64) | 0.011 |
| **Model 3 (adjusted for baseline AS severity, age and renal function)** | | | 0.025 |
| Non-user (reference) | 1 | 0.025 |
| Unfavourable DPP-4 inhibitor | 0.858 (0.49 to 1.52) | 0.597 |
| Favourable DPP-4 inhibitor | 0.116 (0.02 to 0.55) | 0.007 |

AS, aortic stenosis; DPP-4, dipeptidyl peptidase-4.

**Figure 4** Risk of progression to severe aortic stenosis after adjustment for age, baseline renal function and baseline severity of aortic stenosis according to diabetes medication. DPP-4, dipeptidyl peptidase-4.
AS progression. As such, we observed that the frequency of AS progression was the lowest in patients who received favourable DPP-4 inhibitors with favourable anticalcification effect and high H:P concentration ratio.

DPP-4 inhibitors are currently being used for treatment of type 2 diabetes mellitus; the use of DPP-4 inhibitors is not accompanied by weight gain and carries a low risk of hypoglycaemia. As the actions of these drugs are based on restoration of physiological incretin effect, absence of inducible hypoglycaemia in normal controls has been well demonstrated, which supports successful drug repositioning to prevent AS progression in patients without diabetes. Based on this, a phase II clinical trial for patients without diabetes with mild-to-moderate AS is ongoing with evogliptin (NCT04055883), which is a long-acting DPP-4 inhibitor and has the most favourable effects in our experimental study. One potential issue is possible worsening of heart failure reported in several clinical trials. Different results were reported using a different DPP-4 inhibitor, and an analysis of big data from large cohorts of patients with diabetes (up to 1,500,000) reported that incretin-based drugs were not associated with an increased risk of hospitalisation for heart failure. We believe that this potential safety issue does not preclude from doing a clinical trial for successful drug repositioning of DPP-4 inhibitors.

Our study has several limitations. Although we screened more than several hundred thousand echocardiographic examinations in three large-sized tertiary referral hospitals, the number of patients included in the final analysis was rather small and adherence to medication could not be adequately evaluated in this retrospective study. Thus, our findings should be confirmed in a larger patient cohort. Also, as we only included AS patients with diabetes, our observations may not be directly applicable to AS patients without diabetes; a randomised clinical trial incorporating AS patients without diabetes would be useful to broaden the applicability of our results. Lastly, we used an arbitrary binary classification of DPP-4 inhibitors (favourable vs unfavourable) based on an adjusted H:P ratio. The best cut-off value of the index that we proposed could not be determined.

Moreover, as we could not specifically measure valvular concentration of each drug, valvular DPP-4 activity after treatment cannot be evaluated; thus, the clinical implication of the adjusted H:P ratio we calculated needs to be further tested. In addition, we only used alkaline phosphatase activity assessment for comparison of pharmacodynamic properties of different DPP-4 inhibitors, but it can be also evaluated using different experimental models.

CONCLUSIONS

The currently available DPP-4 inhibitors used for diabetes control showed heterogeneous cardiac tissue distribution profiles and anticalcifying effects on aortic VICs. Our retrospective study on patients with diabetes and mild-to-moderate AS showed that DPP-4 inhibitors may be effective as disease-modifying agents for AS, as DPP-4 inhibitors with favourable tissue distribution profile and anticalcification effects were associated with smaller frequency of severe AS progression. These results should be considered in the preparation of randomised clinical trials on the repositioning of DPP-4 inhibitors for AS.

Author affiliations

Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
2Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
3Division of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
4Convergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
5Division of Cardiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
6Division of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Acknowledgements The authors thank the Drug Metabolism and Pharmacokinetics (DMPK) core at the Convergence Medicine Research Center, Asan Medical Center for support and instrumentation. The authors also thank Dr Joon Seo Lim from the Scientific Publications Team at Asan Medical Center for his editorial assistance in preparing this manuscript.

Contributors SL and S-AL participated in the study design and analysis and interpretation of the final data, as well as in the drafting and approval of the final manuscript. BC, Y-JK and SJO were involved in vivo animal experiments for pharmacokinetic–pharmacodynamic modelling and statistical analysis. H-DC, EKK, D-HK, G-YC, J-MS, SWP and D-HK were involved in the recruitment of participants from clinics. J-KS was responsible for the design and supervision of the study and revision of the manuscript.

Funding This research was supported by the Korea Drug Development Fund, funded by the Ministry of Science and ICT, Ministry of Trade, Industry and Energy, and Ministry of Health and Welfare (KDDF-201609-12, Republic of Korea).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval The respective institutional review boards of each institution approved the protocols of this study. All animal experiments and protocols were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Asan Institute for Life Sciences in Asan Medical Center (Seoul, Republic of Korea).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Please contact the corresponding author for our data.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Seung-Ah Lee http://orcid.org/0000-0001-6964-8356
Goo-Yeong Cho http://orcid.org/0000-0002-7067-5525
Jae-Kwan Song http://orcid.org/0000-0002-6469-801X

REFERENCES
1. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National heart and lung and blood Institute aortic stenosis Working Group. executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783–91.
2. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011;108:1392–412.
3. Choi B, Lee S, Kim S-M, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation 2017;135:1935–50.
4. Rameshrad M, Razavi BM, Ferns GAA, et al. Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. Daru 2019;27:341–60.
5. Danhof M, de Lange ECM, Della Pasqua OE, et al. Mechanism-Based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008;29:186–91.
6. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 2012;60:1854–63.
7. Cowell SJ, Newby DE, Prescott KJ, et al. Scottish aortic stenosis and lipid lowering trial, impact on regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389–97.
8. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343–56.
9. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2012;131:206–14.
10. Thanassoulis G. Charge Extracoronary calcium Working Group. genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503–12.
11. Zheng KH, Tsimikas S, Fawwad T, et al. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J Am Coll Cardiol 2019;73:2150–62.
12. Que X, Hung M-Y, Yeang C, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolemic mice. Nature 2018;558:301–6.
13. Schafer S, Viswanathan S, Widjaja AA, et al. If-11 is a crucial determinant of cardiovascular fibrosis. Nature 2017;552:110–5.
14. Herman GA, Stein PP, Thornberry NA, et al. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007;81:761–7.
15. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141–51.
16. Nyström T, Bodegard J, Nathanson D, et al. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 2017;123:199–208.
17. Gu N, Park MK, Kim T-E, et al. Multiple-Dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther 2014;8:1709–21.
18. Packer M. Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. JACC Heart Fail 2018;6:445–51.
19. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–42.
20. Filion KB, Arozullah L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016;374:1145–54.